© 1993 by Oxford University Press
Journal of the National Cancer Institute, Vol. 85, No. 1, 36-40,
January 6, 1993
© 1993 Oxford University Press
Secondary Leukemia Associated With a Conventional Dose of Etoposide: Review of Serial Germ Cell Tumor Protocols
Division of Hematology/Oncology, Department of Medicine, Indiana University School of Medicine Indianapolis, Ind.
Correspondence to: Craig R. Nichols, M.D., Rm. 1730, Indiana University Hospital, 550 N. University Blvd., Indianapolis, IN 46202-5167
Background: Case reports have suggested that treatment with high-dose etoposide can result in development of a unique secondary leukemia. Purpose: This study was designed to estimate the risk of developing leukemia for patients receiving conventional doses of etoposide along with cisplatin and bleornycin. Methods: We reviewed the records at Indiana University of all untreated patients entering clinical trials using etoposide at conventional doses (cumulative dose, 2000 mg/rn2 or less) for germ cell cancer between 1982 and 1991. The records of all patients who received a chemotherapy regimen containing etoposide, ifosfamide, or cisplatin after failing to respond to primary chemotherapy were also reviewed. Results: Between 1982 and 1991, 538 patients entered serial clinical trials with planned cumulative etoposide doses of 1500–2000 mg/rn2 in combination with cisplatin plus either ifosfamide or bleomycin. Of these 538 patients, 348 received an etoposide combination as initial chemotherapy and 190 received etoposide as part of salvage treatment. To date, 315 patients are alive, with median follow-up of 4.9 years, and 337 patients have had follow-up beyond 2 years. Two patients (0.37%) developed leukemia. One developed acute undifferentiated leukemia with a t(4;11) (q21;q23) cytogenetic abnormality 2.0 years after starting etoposide-based therapy, and one developed acute myelomonoblastic leukemia with no chromosome abnormalities 2.3 years after beginning chemotherapy. During this period, several hundred patients were treated with etoposide-based chemotherapy and did not enter clinical trials. Three of these patients are known to have developed hematologic abnormalities, including one patient with acute monoblastic leukemia with a t(11;19)(q13;p13) abnormality. Conclusions: Secondary leukemia after treatment with a conventional dose of etoposide does occur, but the low incidence does not alter the risk-to-benefit ratio of etoposide-based chemotherapy in germ cell cancer. Implications: The reports of leukemia associated with high doses of etoposide emphasize the need for diligent follow-up of patients and make careful risk-to- benefit analysis imperative. [J NatI Cancer Inst 85:36–40, 1993]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. M. Gershenson Management of Ovarian Germ Cell Tumors J. Clin. Oncol., July 10, 2007; 25(20): 2938 - 2943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. O. Smith, M. Berwick, C. F. Verschraegen, C. Wiggins, L. Lansing, C. Y. Muller, and C. R. Qualls Incidence and Survival Rates for Female Malignant Germ Cell Tumors. Obstet. Gynecol., May 1, 2006; 107(5): 1075 - 1085. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Houck, R. Abonour, G. Vance, and L. H. Einhorn Secondary Leukemias in Refractory Germ Cell Tumor Patients Undergoing Autologous Stem-Cell Transplantation Using High-Dose Etoposide J. Clin. Oncol., June 1, 2004; 22(11): 2155 - 2158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. B. Leonard, L. B. Travis, K. Addya, G. M. Dores, E. J. Holowaty, K. Bergfeldt, D. Malkin, B. A. Kohler, C. F. Lynch, T. Wiklund, et al. p53 Mutations in Leukemia and Myelodysplastic Syndrome after Ovarian Cancer Clin. Cancer Res., May 1, 2002; 8(5): 973 - 985. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Vaughn, G. A. Gignac, and A. T. Meadows Long-Term Medical Care of Testicular Cancer Survivors Ann Intern Med, March 19, 2002; 136(6): 463 - 470. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Hosing, M. Munsell, S. Yazji, B. Andersson, D. Couriel, M. de Lima, M. Donato, J. Gajewski, S. Giralt, M. Korbling, et al. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma Ann. Onc., March 1, 2002; 13(3): 450 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Strumberg, S. Brugge, M. W. Korn, S. Koeppen, J. Ranft, G. Scheiber, C. Reiners, C. Mockel, S. Seeber, and M. E. Scheulen Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer Ann. Onc., February 20, 2002; 13(2): 229 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Travis, M. Andersson, M. Gospodarowicz, F. E. van Leeuwen, K. Bergfeldt, C. F. Lynch, R. E. Curtis, B. A. Kohler, T. Wiklund, H. Storm, et al. Treatment-Associated Leukemia Following Testicular Cancer J Natl Cancer Inst, July 19, 2000; 92(14): 1165 - 1171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Krishnan, S. Bhatia, M. L. Slovak, D. A. Arber, J. C. Niland, A. Nademanee, H. Fung, R. Bhatia, A. Kashyap, A. Molina, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors Blood, March 1, 2000; 95(5): 1588 - 1593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Sweeney, B. P. Hermans, D. K. Heilman, R. S. Foster, J. P. Donohue, and L. H. Einhorn Results and Outcome of Retroperitoneal Lymph Node Dissection for Clinical Stage I Embryonal Carcinoma-Predominant Testis Cancer J. Clin. Oncol., January 14, 2000; 18(2): 358 - 358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bokemeyer, C. Kollmannsberger, C. Meisner, A. Harstrick, J. Beyer, B. Metzner, J. T. Hartmann, H.-J. Schmoll, L. Einhorn, L. Kanz, et al. First-Line High-Dose Chemotherapy Compared With Standard-Dose PEB/VIP Chemotherapy in Patients With Advanced Germ Cell Tumors: A Multivariate and Matched-Pair Analysis J. Clin. Oncol., November 1, 1999; 17(11): 3450 - 3456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. T. Schneider, E. Hilgenfeld, D. Schwabe, W. Behnisch, A. Zoubek, R. Wessalowski, and U. Gobel Acute Myelogenous Leukemia After Treatment for Malignant Germ Cell Tumors in Children J. Clin. Oncol., October 1, 1999; 17(10): 3226 - 3233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Garnick and J. A. Ferry Case 40-1997- A 23-Year-Old Man with a Mediastinal Embryonal Carcinoma and Hematologic Abnormalities N. Engl. J. Med., December 25, 1997; 337(26): 1904 - 1912. [Full Text] [PDF]
|
|
|
|
|
|
G. J. Bosl and R. J. Motzer Testicular Germ-Cell Cancer N. Engl. J. Med., July 24, 1997; 337(4): 242 - 254. [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Hande The Importance of Drug Scheduling in Cancer Chemotherapy: Etoposide as an Example Oncologist, August 1, 1996; 1(4): 234 - 239. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hande The importance of drug scheduling in cancer chemotherapy: etoposide as an example Stem Cells, January 1, 1996; 14(1): 18 - 24. [Abstract]
|
|